Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

ClinicalKey

Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials

Scientists gave a standing ovation at a Chicago conference for clinical trial results of daraxonrasib, a pancreatic cancer drug developed by

Daraxonrasib drug nearly doubles survival in advanced pancreatic cancer, oncologist reports

Pancreatic cancer has extremely low survival rates (97% mortality within 5 years for metastatic cases) due to lack of effective screening an

Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients

An experimental drug called daraxonrasib has become the first treatment to substantially extend the lives of pancreatic cancer patients in a

New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'

Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma

Experimental pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients

Researchers reported that daraxonrasib, a novel daily pill, helped people with advanced pancreatic cancer live longer by blocking a mutated